4 big analyst picks Alcon upgraded to Outperform after Q1 beat Pro Recap

NEO Stock  USD 14.50  0.32  2.26%   
About 55% of NeoGenomics' investors are presently thinking to get in. The analysis of overall sentiment of trading NeoGenomics stock suggests that some investors are interested at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Baird upgraded Alcon to Outperform from Neutral and raised its price target to 90.00 from 75.00 following Q1 earnings. Shares jumped more than 7 percent pre-market today after the company reported its Q1 results, with EPS of 0.70 and revenue of 2.3 billion beating the consensus estimates. BTIG upgraded NeoGenomics to Buy from Neutral with a price target of 25.00, noting it was impressed by the change in underlying growth at the company since the new management team has taken over.

Read at finance.yahoo.com
Yahoo News
  

NeoGenomics Fundamental Analysis

We analyze NeoGenomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

NeoGenomics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

NeoGenomics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeoGenomics stock to make a market-neutral strategy. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics with similar companies.

Peers

NeoGenomics Related Equities

GHGuardant Health   4.59   
0%
70.0%
TWSTTwist Bioscience   3.75   
0%
57.0%
NTRANatera   2.67   
0%
40.0%
SHCSotera Health   2.18   
0%
33.0%
CDNACaredx   2.16   
0%
33.0%
NEOGNeogen   1.79   
0%
27.0%
MYGNMyriad Genetics   1.45   
0%
22.0%
ACRSAclaris Therapeutics   1.17   
0%
17.0%
MTDMettler Toledo   0.02   
0%
1.0%
IQVIQVIA Holdings   0.13   
1.0%
0%
CSTLCastle Biosciences   0.37   
5.0%
0%
QGENQiagen NV   0.53   
8.0%
0%
CRLCharles River   0.94   
14.0%
0%
ICLRICON PLC   0.98   
14.0%
0%
BDSXBiodesix   6.54   
100.0%
0%
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Business Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.